[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560604":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":10,"responsibleParty":25,"collaborators":10,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":31,"acronym":10,"eligibilityCriteria":32,"healthyVolunteers":29,"sex":33,"minAge":34,"maxAge":10,"enrollmentInfo":35,"targetDuration":10,"studyType":38,"phases":10,"briefSummary":39,"conditions":40,"keywords":10,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":10},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"HBV cohort",null,"2000 HBsAg positive patients during 2016.7-2019.12",{"label":13,"type":10,"description":14,"interventionNames":10},"HCV cohort","500 HCV Ab positive and HCV RNA positive patients during 2020.7-2023.12",[16],{"name":17,"affiliation":5,"role":18},"Qing Xie","PRINCIPAL_INVESTIGATOR",[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Honglian Gui","CONTACT","+8613564725017","lillian_ghl@163.com",{"type":26,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100560604","current-situation-of-health-care-in-women-with-hbv-or-hcv-infection-100560604",false,"NCT06579313","Current Situation of Health Care in Women With HBV or HCV Infection","Inclusion Criteria:\n\nHBV Cohort -\n\n* ≥18 years old\n* serum HBsAg positive for \\>6 months\n* Treatment naïve or,\n* Patients who had been previously treated for HBV but discontinued for at least 1 year before enrollment\n\nHCV Cohort -\n\n* ≥18 years old\n* HCV-Ab positive\n* HCV RNA positive\n* Treatment naïve or,\n* Patients who had been previously treated for HCV with a regimen containing interferon and not had a sustained virologic response.\n\nExclusion Criteria:\n\n* HBV\u002FHCV Co-infection\n* HIV\n* History of hepatic decompensation or hepatocellular carcinoma\n* Other carcinoma\n* Other severe liver disease\n* Severe Comorbidity like cardiovascular disease, diabetes etc.\n* Patients who had discontinued previous HCV treatment because of an adverse event.\n* Patients who had previously received any nucleotide analogue HCV NS5B inhibitor or any NS5A inhibitor\n* Patients who had discontinued previous HBV treatment because of an adverse event.","ALL","18 Years",{"count":36,"type":37},2500,"ESTIMATED","OBSERVATIONAL","A multicenter, retrospective study conducted in male and female population infected with HBV or HCV in east China. HCV part, study will enroll 500 HCV antibody positive and HCV RNA positive patients during 2020.7-2023.12 and then observe the characteristics, duration from diagnosis to treatment, treatment rate and sustained virologic response (SVR12) among eligible female and male patients. HBV part, study will enroll 2000 HBsAg positive patients during 2016.7-2019.12 and then observe the clinical characteristics, natural history, duration from diagnosis to treatment, treatment rate and adherence among eligible female and male patients.",[41,42],"HBV","HCV","NOT_YET_RECRUITING","2024-08-29",{"date":46,"type":47},"2024-08-30","ACTUAL",{"date":49,"type":37},"2024-09-01",{"date":51,"type":37},"2025-07-31",{"name":5,"class":6}]